Neuphoria Therapeutics Inc (NEUP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.77+0.27%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Neuphoria is pioneering new mental health treatments using psychedelics. It has a promising pipeline targeting unmet needs. The company’s recent merger talks could strengthen its position. Its free cash flow yield is high at 9.64%, showing potential value.
Neuphoria is loss-making with no revenue expected soon. It faces regulatory and listing challenges. The recent 34.5% stock drop shows investor doubts. Its EPS is forecasted negative at -2.43 in 2027, signaling ongoing losses.
The market prices in a high-risk, loss-making biotech with no near-term revenue. There is no clear consensus revenue growth or fair value, reflecting uncertainty. Our view sees potential but also significant execution risk.
Breaks if: cash runway insufficient to fund operations through FY27
Breaks if: no significant clinical progress or regulatory setbacks by FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
NEUP is a speculative growth investment, focusing on developing immunotherapy treatments. The current thesis state is mixed, with recent management priorities indicating a need for financing and ongoing clinical development.
The market appears to have priced in a cheap valuation relative to peers, but there is a high level of risk given the company's loss-making status and the low confidence in management's execution. Expectations may hinge on upcoming guidance and sector performance.
Fundamentals are likely to remain challenging in the near term, as the company has a significant probability of missing earnings expectations. The recent financial performance has been neutral, and the need for financing suggests ongoing operational difficulties.
The long-term thesis hinges on the successful completion of the merger with Scancell, the ability to raise necessary financing, and advancements in the iSCIB1+ trial. Additionally, the performance of sector bellwethers could influence NEUP's trajectory.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: merger or partnership fails or is abandoned by mid-2027
In the next 1 to 3 years, NEUP's outlook is uncertain, with several risks and dependencies on execution and market conditions. Not investment advice.